MX2023011442A - Un inhibidor de pi3k-delta para usarse en regimenes de tratamiento. - Google Patents

Un inhibidor de pi3k-delta para usarse en regimenes de tratamiento.

Info

Publication number
MX2023011442A
MX2023011442A MX2023011442A MX2023011442A MX2023011442A MX 2023011442 A MX2023011442 A MX 2023011442A MX 2023011442 A MX2023011442 A MX 2023011442A MX 2023011442 A MX2023011442 A MX 2023011442A MX 2023011442 A MX2023011442 A MX 2023011442A
Authority
MX
Mexico
Prior art keywords
pi3k
treatment regimens
delta inhibitor
compound
pi3kd
Prior art date
Application number
MX2023011442A
Other languages
English (en)
Spanish (es)
Inventor
Der Veen Lars Van
Zoë Johnson
Catherine Pickering
Michael Lahn
Rebeca Zorrilla
Original Assignee
Ionctura Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104416.9A external-priority patent/GB202104416D0/en
Priority claimed from GBGB2117511.2A external-priority patent/GB202117511D0/en
Application filed by Ionctura Sa filed Critical Ionctura Sa
Publication of MX2023011442A publication Critical patent/MX2023011442A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
MX2023011442A 2021-03-29 2022-03-29 Un inhibidor de pi3k-delta para usarse en regimenes de tratamiento. MX2023011442A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2104416.9A GB202104416D0 (en) 2021-03-29 2021-03-29 Treatment reginmens
GBGB2117511.2A GB202117511D0 (en) 2021-12-03 2021-12-03 Treatment regimens
PCT/EP2022/058283 WO2022207646A1 (en) 2021-03-29 2022-03-29 A pi3k-delta inhibitor for use in treatment regimens

Publications (1)

Publication Number Publication Date
MX2023011442A true MX2023011442A (es) 2023-10-18

Family

ID=81388915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011442A MX2023011442A (es) 2021-03-29 2022-03-29 Un inhibidor de pi3k-delta para usarse en regimenes de tratamiento.

Country Status (17)

Country Link
US (2) US12605389B2 (cg-RX-API-DMAC7.html)
EP (2) EP4313058B1 (cg-RX-API-DMAC7.html)
JP (1) JP7839803B2 (cg-RX-API-DMAC7.html)
AU (1) AU2022251843B2 (cg-RX-API-DMAC7.html)
CA (1) CA3212731A1 (cg-RX-API-DMAC7.html)
DK (1) DK4313058T3 (cg-RX-API-DMAC7.html)
ES (1) ES3031295T3 (cg-RX-API-DMAC7.html)
FI (1) FI4313058T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250516T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071610T2 (cg-RX-API-DMAC7.html)
LT (1) LT4313058T (cg-RX-API-DMAC7.html)
MX (1) MX2023011442A (cg-RX-API-DMAC7.html)
PL (1) PL4313058T3 (cg-RX-API-DMAC7.html)
PT (1) PT4313058T (cg-RX-API-DMAC7.html)
RS (1) RS66754B1 (cg-RX-API-DMAC7.html)
SI (1) SI4313058T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022207646A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024184266A1 (en) * 2023-03-03 2024-09-12 Ionctura Sa Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy
JP2026510567A (ja) * 2023-03-03 2026-04-08 アイオンクチュラ・ソシエテ・アノニム 血液悪性腫瘍の治療におけるロギノリシブ及びbcl-2阻害剤の組み合わせ
GB202418087D0 (en) 2024-12-10 2025-01-22 Ionctura Sa Biomarkers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012005518A (es) 2009-11-13 2012-06-19 Merck Serono Sa Derivados de pirazol amina triciclica.
WO2014121901A1 (en) * 2013-02-07 2014-08-14 Merck Patent Gmbh Polymorphic forms
US9986723B2 (en) 2014-10-22 2018-06-05 The Board Of Regents Of The University Of Texas System Screen and use of therapeutics for pancreatic ductal adenocarcinoma
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma

Also Published As

Publication number Publication date
CA3212731A1 (en) 2022-10-06
US20260224587A1 (en) 2026-08-06
PT4313058T (pt) 2025-06-02
LT4313058T (lt) 2025-05-26
RS66754B1 (sr) 2025-05-30
AU2022251843B2 (en) 2026-04-09
HRP20250516T1 (hr) 2025-06-20
SI4313058T1 (sl) 2025-07-31
DK4313058T3 (da) 2025-05-12
EP4744651A2 (en) 2026-05-20
ES3031295T3 (en) 2025-07-07
US20240058351A1 (en) 2024-02-22
HUE071610T2 (hu) 2025-09-28
PL4313058T3 (pl) 2025-06-23
FI4313058T3 (fi) 2025-04-30
JP2024518685A (ja) 2024-05-02
AU2022251843A1 (en) 2023-10-05
EP4313058B1 (en) 2025-03-05
WO2022207646A1 (en) 2022-10-06
JP7839803B2 (ja) 2026-04-02
EP4313058A1 (en) 2024-02-07
US12605389B2 (en) 2026-04-21

Similar Documents

Publication Publication Date Title
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CL2019000268A1 (es) Composición de cannabis.
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
BR112018075682A2 (pt) inibidores de papd5 e papd7 para tratamento de infecção pela hepatite b
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
MX2020002150A (es) Terapia de combinación para el tratamiento del cáncer.
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
AR119158A1 (es) Tratamientos de angioedema hereditario
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CO2022000426A2 (es) Inhibidores de calicreína plasmática
BR112022014861A2 (pt) Métodos de tratamento para deficiência de alfa-1 antittripsina
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
PE20242201A1 (es) Tratamiento de neurofibromas cutaneos con mirdametinib
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
AR119159A1 (es) Tratamientos de angioedema
CO2019009000A2 (es) Combinaciones farmacéuticas para tratar cáncer
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
CL2022001516A1 (es) Compuesto y composición como inhibidor de quinasa del receptor pdgf
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
BR112019008698A2 (pt) método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
AR080541A1 (es) Tratamiento para la endometriosis
BR112021006388A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero